Myofascial edema of gastrocnemius: A prominent MRI characteristic in dermatomyositis patients with anti‐transcriptional intermediate factor 1‐γ antibody
CNS Neuroscience & Therapeutics · 2024
DOI: 10.1111/cns.14647 ↗Kurz gefasst
Beobachtungsstudie in der Zeitschrift CNS Neuroscience & Therapeutics, 2024. Verfasst von Chao Zhen und 6 weiteren Autor:innen. Beteiligte Einrichtung: Research Institute of Neuromuscular and Neurodegenerative Diseases and Department of Neurology, Qilu Hospital of Shandong University, Jinan, China. Hauptthemen laut MEDLINE: Dermatomyositis. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Natural Science Foundation of Shandong Province, National Natural Science Foundation of China.
Abstract (Originalsprache)
Aims
This study was designed to evaluate the magnetic resonance imaging (MRI) patterns of the lower limb muscles in dermatomyositis (DM) with anti‐transcriptional intermediate factor 1‐γ (anti‐TIF1‐γ) antibody.
Methods
This retrospective, observational, cross‐sectional study enrolled 12 adult DM patients with anti‐TIF1‐γ antibody. Muscles were assessed for fascial edema, subcutaneous‐tissue edema, muscle edema, and fatty replacement. These features were analyzed in relation to clinical characteristics.
Results
All 12 patients underwent hip and thigh MRI, and 8 completed calf MRI. All patients showed myofascial edema, muscle edema, and fatty replacement, and 8 out of 12 further exhibited subcutaneous‐tissue edema. Specifically, myofascial edema of the gastrocnemius was observed in all patients (8/8). The vastus intermedialis and vastus lateralis muscles showed the most severe muscle edema, whereas the caput breve of the biceps femoris, semitendinosus, and soleus muscles exhibited the most severe fatty replacement. Although only 1 patient exhibited asymmetric muscle weakness, 9 showed asymmetric muscle edema, and 10 showed asymmetric fatty replacement. Changes in muscle edema positively correlated with creatine kinase (CK) levels.
Conclusions
Myofascial edema of gastrocnemius was a prominent characteristic of anti‐TIF1‐γ‐positive DM. Early detection of muscle edema, as well as CK levels, may be helpful for monitoring disease activity.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Research Institute of Neuromuscular and Neurodegenerative Diseases and Department of Neurology, Qilu Hospital of Shandong University, Jinan, China.
- Department of Neurology, Qingdao Hospital, University of Health and Rehabilitation Sciences (Qingdao Municipal Hospital), Qingdao, China.
- Department of Radiology, Qilu Hospital of Shandong University, Jinan, Shandong, China.
- Department of Central Laboratory and Mitochondrial Medicine Laboratory, Qilu Hospital (Qingdao), Cheeloo College of Medicine, Shandong University, Qingdao, China.
- Brain Science Research Institute, Shandong University, Jinan, China.
ORCID-Profile: Chao Zhen, Chuanzhu Yan, Tingjun Dai, Ying Hou
Förderung
- Natural Science Foundation of Shandong Province
- National Natural Science Foundation of China
Zitieren
APA
Zhen, C., Zhao, B., He, J., Wei, L., Yan, C., Dai, T., & Hou, Y. (2024). Myofascial edema of gastrocnemius: A prominent MRI characteristic in dermatomyositis patients with anti‐transcriptional intermediate factor 1‐γ antibody. CNS Neuroscience & Therapeutics. https://doi.org/10.1111/cns.14647
Vancouver
Zhen C, Zhao B, He J, Wei L, Yan C, Dai T, et al. Myofascial edema of gastrocnemius: A prominent MRI characteristic in dermatomyositis patients with anti‐transcriptional intermediate factor 1‐γ antibody. CNS Neuroscience & Therapeutics. 2024. doi:10.1111/cns.14647
BibTeX
@article{Zhen2024,
author = {Zhen, Chao and Zhao, Bing and He, Jingzhen and Wei, Li and Yan, Chuanzhu and Dai, Tingjun and Hou, Ying},
title = {Myofascial edema of gastrocnemius: A prominent MRI characteristic in dermatomyositis patients with anti‐transcriptional intermediate factor 1‐γ antibody},
journal = {CNS Neuroscience & Therapeutics},
year = {2024},
doi = {10.1111/cns.14647}
}
EUVIMED